http://www.pharmexeceurope.com/europharmexec Latest content from Pharmaceutical Executive Europe, the leading strategy-based, business management portal and e-zine for senior executives, corporate strategists and sales & marketing leaders in the European pharmaceutical industry. 2008-05-17T18:33:14Z http://www.pharmexeceurope.com/europharmexec/Recruitment%3A+R%26D/16-May-08-Pfizer-names-new-Senior-VP-of-its-Oncolo/ArticleStandard/Article/detail/517386?ref=25 Garry A. Nicholson has been named as Pfizer's new Senior Vice President and General Manager of the company?s newly formed Oncology Business Unit. 2008-05-16T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/517386null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Sales+%26+Marketing/16-MAY-08-Oncology-drug-sales-will-grow-faster-tha/ArticleStandard/Article/detail/517350?ref=25 According to IMS Health, sales of cancer drugs will grow at nearly double the rate of the global pharmaceutical market and could reach $80 billion by 2012. 2008-05-16T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/517350null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Finance%2C+M%26A/15-May-08-Pfizer-may-be-looking-to-buy-MediGene/ArticleStandard/Article/detail/517160?ref=25 The word on the grapevine is that Pfizer is looking to take over the German Biotech company, MediGene. 2008-05-15T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/517160null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Supply+Chain%2C+Technology/15-May-08-Black-market-medicines-are-an-increasing/ArticleStandard/Article/detail/517156?ref=25 The European Federation of Pharmaceutical Industries and Associations (EFPIA) has said that the industry needs to do more to prevent the increase in counterfeit medicine sales. 2008-05-15T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/517156null HTML http://www.pharmexeceurope.com/europharmexec/The-10-Biggest-Mistakes-Sales-People-Make/ArticleStandard/Article/detail/516834?ref=25 To help answer the question 'What makes a sales person successful?' we have to ask 'What are the biggest mistakes a sales person makes?' Avoid those and you might find yourself doing rather well, says Lars Tewes. 2008-05-14T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/516834null HTML http://www.pharmexeceurope.com/europharmexec/Does-your-company-qualify-for-EMEA-support/ArticleStandard/Article/detail/516833?ref=25 Smaller firms developing advanced therapy medicines will be entitled to expert assistance from the European Medicines Agency as from the end of this year, reports Reflector. 2008-05-14T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/516833null HTML http://www.pharmexeceurope.com/europharmexec/Learn-about-Condition-Branding/ArticleStandard/Article/detail/516835?ref=25 Join the IMS workshop dedicated to a groundbreaking new approach to marketing. 2008-05-14T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/516835null HTML http://www.pharmexeceurope.com/europharmexec/Is-your-company-operating-at-peak-efficiency/ArticleStandard/Article/detail/516836?ref=25 If not, running a virtual plant and 'simulating the future' can help you get there. 2008-05-14T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/516836null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Regulatory%2C+Legal/13-May-08-Oral-Hycamtin-approved-in-Europe-for-sma/ArticleStandard/Article/detail/516456?ref=25 GlaxoSmithKline (GSK) has received approval from the European Commission for oral Hycamtin (topotecan hard capsules) as a treatment for relapsed small cell lung cancer. 2008-05-13T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/516456null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Corporate+Strategy/13-May-08-Merck-enters-into-development-deal-with-/ArticleStandard/Article/detail/516455?ref=25 Merck & Co has entered into a strategic product development deal with Ranbaxy, India's largest pharmaceutical company. 2008-05-13T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/516455null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Finance%2C+M%26A/12-May-08-Sanofi-Aventis-shares-fall/ArticleStandard/Article/detail/516141?ref=25 Shares in Sanofi-Aventis have gone down by 4.3% following the announcement by a Swiss generics company that it is close to getting approval for its version of the anti-platelet agent, Plavix. 2008-05-12T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/516141null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Finance%2C+M%26A/12-May-08-EUSA-acquires-Cytogen/ArticleStandard/Article/detail/516140?ref=25 EUSA Pharma has completed its acquisition of Cytogen Corporation, following approval by Cytogen's shareholders. 2008-05-12T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/516140null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Sales+%26+Marketing/12-May-08-Symbicort-patent-revoked/ArticleStandard/Article/detail/516142?ref=25 AstraZeneca has been told that its patents for Symbicort (formoterol/budesonide), as a treatment for chronic obstructive pulmonary disease (COPD), are no longer valid in Europe. 2008-05-12T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/516142null HTML http://www.pharmexeceurope.com/europharmexec/News/08-May-08-GSK-acquire-Sitris-Pharmaceuticals/ArticleStandard/Article/detail/515450?ref=25 GlaxoSmithKline (GSK) has taken over Sitris Pharmaceuticlas as part of an agreement involving the acquisition of the company's research portfolio. 2008-05-08T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/192008/515450null HTML http://www.pharmexeceurope.com/europharmexec/News/08-May-08-New-HIV-drug-receives-marketing-authoris/ArticleStandard/Article/detail/515451?ref=25 Boehringer Ingelheim has been granted full marketing authorisation by the European Commission for its HIV protease inhibitor (PI), Aptivus (tipranavir). 2008-05-08T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/192008/515451null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+R%26D/06-May-08-Pfizer-to-open-biotech-plant-in-Ireland/ArticleStandard/Article/detail/514784?ref=25 Pfizer is to invest 190 million euros in a new biotech plant in Ireland for the production of experimental medicines. 2008-05-06T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/192008/514784null HTML http://www.pharmexeceurope.com/europharmexec/News/06-May-08-Application-for-Iressa-to-be-sold-in-Eur/ArticleStandard/Article/detail/514785?ref=25 AstraZeneca has applied to sell its lung cancer drug Iressa in Europe as a treatment for selected patients. 2008-05-06T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/192008/514785null HTML http://www.pharmexeceurope.com/europharmexec/News/02-May-08-Court-of-Appeal-rules-against-NICE/ArticleStandard/Article/detail/514046?ref=25 The Court of Appeal in England has ruled that the National Institute for Health and Clinical Excellence (NICE) was insufficiently transparent when disclosing why it had decided to limit access to Alzheimer's drugs. 2008-05-02T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/182008/514046null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Corporate+Strategy/02-May-08-New-Corporate-Executive-Team-for-GSK/ArticleStandard/Article/detail/514044?ref=25 GlaxoSmithKline has announced a number of changes to its Corporate Executive Management team which will take effect when Andrew Witty assumes the role of Chief Executive Officer on May 22nd. 2008-05-02T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/182008/514044null HTML http://www.pharmexeceurope.com/europharmexec/News/02-May-08-IMI-up-and-running-in-Europe/ArticleStandard/Article/detail/514045?ref=25 A partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations, called Innovative Medicines Initiative (IMI), is now up and running. 2008-05-02T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/182008/514045null HTML http://www.pharmexeceurope.com/europharmexec/Beyond-the-Blockbuster-What-Can-Big-Pharma-Learn-f/ArticleStandard/Article/detail/513217?ref=25 Beyond the Blockbuster: What Can Big Pharma Learn from Mid-tier and Specialty Pharma? 2008-05-01T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/182008/513217/WPPEE_flash.jpg PDF http://www.pharmexeceurope.com/europharmexec/Articles%3A+Corporate+Strategy/What-can-Big-Pharma-learn-from-mid-tier-and-specia/ArticleStandard/Article/detail/513188?ref=25 Read Pharm Exec Europe's exclusive new White Paper by Gerhard Symons. 2008-05-01T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/182008/513188null HTML http://www.pharmexeceurope.com/europharmexec/Events%3A+Corporate+Strategy/What-will-shape-the-pharma-world-in-2008/ArticleStandard/Article/detail/513185?ref=25 Attend IMS's INTELLIGENCE.360 preview to assess the events that transformed the global pharmaceutical landscape in 2007 and predict the trends of the year ahead. 2008-05-01T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/182008/513185null HTML http://www.pharmexeceurope.com/europharmexec/Articles%3A+Corporate+Strategy/How-all-employee-recognition-can-help-retention/ArticleStandard/Article/detail/513186?ref=25 Julian Bazley offers some pointers for keeping your staff happy and, importantly, feeling valued. 2008-05-01T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/182008/513186null HTML http://www.pharmexeceurope.com/europharmexec/Articles%3A+Regulatory%2C+Legal/Europa--a-site-worse-than-before/ArticleStandard/Article/detail/513184?ref=25 The EU has revamped its pharmaceuticals website, but is its 'entertaining' vision a skewered one? Reflector reports. 2008-05-01T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/182008/513184null HTML http://www.pharmexeceurope.com/europharmexec/Featured+articles/VOTE/ArticleStandard/Article/detail/512920?ref=25 To what extent are you 'digitising' your publications strategy? 2008-04-29T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/182008/512920/vote2_flash.jpg REMOTE http://www.pharmexeceurope.com/europharmexec/News%3A+Sales+%26+Marketing/Want-a-better-view-of-your-complex-promotional-wor/ArticleStandard/Article/detail/512323?ref=25 Find out more at IMS Webinar on May 15th 2008-04-25T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/172008/512323/Magnifyingglass_flash.jpg HTML http://www.pharmexeceurope.com/europharmexec/News/24APRIL-08-AZ-reports-pre-tax-profit-decline-of-21/ArticleStandard/Article/detail/512125?ref=25 Falling US sales of Nexium mar first quarter results. 2008-04-24T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/172008/512125null HTML http://www.pharmexeceurope.com/europharmexec/News/22-April-08-Good-first-quarter-income-for-Novartis/ArticleStandard/Article/detail/511586?ref=25 Novartis has announced that its first-quarter net income from continuing operations has risen 10% over the prior-year, resulting in its shares gaining as much as 5%. 2008-04-22T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/172008/511586null HTML http://www.pharmexeceurope.com/europharmexec/How-do-you-feel-about-being-accessible-247/ArticleStandard/Article/detail/511598?ref=25 Vote 2008-04-22T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/172008/511598/vote2_flash.jpg REMOTE http://www.pharmexeceurope.com/europharmexec/News/18-April-08-Lower-Tamiflu-demand-strikes-Roches-Q1/ArticleStandard/Article/detail/510955?ref=25 First quarter revenue suffers as bird 'flu panic dissipates 2008-04-18T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/162008/510955null HTML http://www.pharmexeceurope.com/europharmexec/Detrusitol-Toilet-head-ad/ArticleStandard/Article/detail/510936?ref=25 Detrusitol 'Toilet head' ad 2008-04-18T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/162008/510936null HTML http://www.pharmexeceurope.com/europharmexec/News/15-April-08-AstraZeneca-and-Ranbaxy-settle-over-Ne/ArticleStandard/Article/detail/510157?ref=25 US victory for blockbuster heartburn treatment. 2008-04-15T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/162008/510157null HTML http://www.pharmexeceurope.com/europharmexec/Interviews+and+comment%3A+Corporate+Strategy/Its-time-for-pharma-to-tell-the-truth/ArticleStandard/Article/detail/509911?ref=25 Why don't doctors trust what pharma reps say about their products? Pierre De Nayer of Citobi tells Pharm Exec Europe that the answer is simple: the industry hasn't been telling the truth. Now it's time to change. 2008-04-15T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/162008/509911/flashnayer_flash.jpg HTML http://www.pharmexeceurope.com/europharmexec/Articles%3A+Sales+%26+Marketing/Do-award-winning-ads-work-for-pharma/ArticleStandard/Article/detail/509910?ref=25 Trevor Acreman questions what makes a successful ad and how success should be defined. 2008-04-15T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/162008/509910/flashtoilet_flash.jpg HTML http://www.pharmexeceurope.com/europharmexec/Interviews+and+comment%3A+Regulatory%2C+Legal/Innovative-Medicines-Initiative-has-lift-off/ArticleStandard/Article/detail/509912?ref=25 Reflector welcomes the upcoming launch of the much-discussed initiative. 2008-04-15T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/162008/509912null HTML http://www.pharmexeceurope.com/europharmexec/Articles%3A+Corporate+Strategy/Friends-in-high-places-connect-with-CEOs-from-othe/ArticleStandard/Article/detail/509913?ref=25 Who can pharma CEOs and MDs turn to for mentoring and guidance? Certainly not each other. But one mentoring service offers a unique opportunity for CEOs from all industries to help each other. 2008-04-15T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/162008/509913/PEEHandshake_flash.jpg HTML http://www.pharmexeceurope.com/europharmexec/News/14-April-08-Russia-is-first-country-to-approve-nov/ArticleStandard/Article/detail/509924?ref=25 Antigenic's Oncophage receives go-ahead for kidney cancer patients. 2008-04-14T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/162008/509924null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Regulatory%2C+Legal/11-April-08-ALIMTA-given-European-stamp-of-approva/ArticleStandard/Article/detail/509588?ref=25 Eli Lilly and Company has been granted European approval for ALIMTA (pemetrexed for injection) to be used histologically for the first-line treatment of advanced non-small-cell lung cancer (NSCLC). 2008-04-11T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/152008/509588null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+R%26D/11-April-08-New-cancer-drug-candidate-in-clinical-/ArticleStandard/Article/detail/509583?ref=25 The Institute of Cancer Research has announced that its drug candidate, GDC-0941, is now in clinical development. 2008-04-11T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/152008/509583null HTML http://www.pharmexeceurope.com/europharmexec/News/07-April-08-New-UK-concerns-for-anti-psychotics-in/ArticleStandard/Article/detail/508104?ref=25 New report suggests that lives may be in danger. 2008-04-07T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/152008/508104null HTML http://www.pharmexeceurope.com/europharmexec/News/07-April-08-Novartis-and-Alcon-in-39-billion-deal/ArticleStandard/Article/detail/508073?ref=25 Swiss company enters into agreement to acquire majority of Alcon. 2008-04-07T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/152008/508073null HTML http://www.pharmexeceurope.com/europharmexec/CURRENT-ISSUE/ArticleStandard/Article/detail/480000?ref=25 View the latest issue of Pharmaceutical Executive Europe for FREE now. 2008-04-01T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/512007/480000null HTML http://www.pharmexeceurope.com/europharmexec/Articles%3A+Corporate+Strategy/Pharma-CFOs-Take-Centre-Stage/ArticleStandard/Article/detail/506520?ref=25 New surveys highlight expanding role of the chief financial officer. 2008-04-01T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/142008/506520null HTML http://www.pharmexeceurope.com/europharmexec/Articles%3A+Corporate+Strategy/It-Can-Be-Easy-Being-Green/ArticleStandard/Article/detail/506517?ref=25 Bolstering your company's recycling strategy can be good for business, says Graham Davy. 2008-04-01T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/142008/506517null HTML http://www.pharmexeceurope.com/europharmexec/Interviews+and+comment%3A+Regulatory%2C+Legal/Anti-counterfeiting-in-Europe-a-breakthrough/ArticleStandard/Article/detail/506516?ref=25 The EU finally is finally starting a new battle in the war against drug counterfeiting, reports Pharm Exec Europe columnist Reflector. 2008-04-01T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/142008/506516null HTML http://www.pharmexeceurope.com/europharmexec/Interviews+and+comment%3A+Supply+Chain%2C+Technology/A-Breath-of-Fresh-Air-151-the-2008-DIA-EuroMeeting/ArticleStandard/Article/detail/506518?ref=25 IT expert George Laszlo explains why he was impressed by last month's 'riskier' European DIA event. 2008-04-01T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/142008/506518null HTML http://www.pharmexeceurope.com/europharmexec/NL-images/ArticleStandard/Article/detail/506548?ref=25 NL images 2008-03-31T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/142008/506548null HTML http://www.pharmexeceurope.com/europharmexec/News/30-Mar-08-Finlands-Oriola-moves-into-Russia/ArticleStandard/Article/detail/506382?ref=25 Finnish pharma company makes two acquisitions in Russia. 2008-03-30T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/142008/506382null HTML http://www.pharmexeceurope.com/europharmexec/News/26-Mar-08-Pharma-CFOs-take-centre-stage/ArticleStandard/Article/detail/505357?ref=25 New surveys highlight the increasing importance of the chief financial officer. 2008-03-26T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/132008/505357null HTML http://www.pharmexeceurope.com/europharmexec/News/March-issue-of-Pharm-Exec-Europe-available-now/ArticleStandard/Article/detail/505150?ref=25 This issue: the value of executive search agencies 2008-03-25T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/132008/505150null HTML http://www.pharmexeceurope.com/europharmexec/Hillary-Obama-or-Mccain/ArticleStandard/Article/detail/504319?ref=25 What will the next president really mean for US healthcare policy? PwC's Sandy Lutz reports. 2008-03-20T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/122008/504319/Votebadge_flash.jpg REMOTE http://www.pharmexeceurope.com/europharmexec/News%3A+Corporate+Strategy/20-MAR-08-Takeda-and-Abbott-split-after-30-years/ArticleStandard/Article/detail/504307?ref=25 Japanese and US giants part ways in North America. 2008-03-20T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/122008/504307null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Regulatory%2C+Legal/18-MAR-08-Mapreg-spinal-drug-granted-orphan-status/ArticleStandard/Article/detail/503596?ref=25 MAP4343 has an identified and validated molecular target: Microtubule Associated Protein type 2 (MAP2). 2008-03-18T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/122008/503596null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Corporate+Strategy/17-MAR-08-Amgen-Lab21-in-Partnership-Agreement-for/ArticleStandard/Article/detail/503285?ref=25 Under the terms of the agreement, leading diagnostics company Lab21 will provide a screening test to indicate which patients are likely to benefit from Amgen's new drug for advanced bowel cancer, Vectibix. 2008-03-17T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/122008/503285null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+R%26D/17-MAR-08-MorphoSys-Crucell-enter-antibody-materia/ArticleStandard/Article/detail/503279?ref=25 The license agreement allows MorphoSys to use Crucell's PER.C6 cell line in the production of clinical grade material for the development of its proprietary therapeutic cancer antibody programme MOR202. 2008-03-17T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/122008/503279null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Finance%2C+M%26A/14-MAR-08-Genmab-and-PDL-close-facility-sale/ArticleStandard/Article/detail/503132?ref=25 The agreement was first announced on February 21st. 2008-03-14T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/112008/503132null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Regulatory%2C+Legal/13-MAR-08-Cobra-Receives-French-Approval/ArticleStandard/Article/detail/502948?ref=25 Cobra Biomanufacturing Plc has received approval for research and development tax credit (Le Crédit d'Impôt Recherche (CIR)) from the French Ministry for Higher Education and Research. 2008-03-13T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/112008/502948null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+R%26D/12-MAR-08-BioInvent-Bayer-sign-antibody-deal/ArticleStandard/Article/detail/502291?ref=25 Under the terms of the agreement, Bayer HealthCare will have a non-exclusive research licence for the use of BioInvent's proprietary n-CoDeR library for the discovery of human monoclonal antibodies. 2008-03-12T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/112008/502291null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Regulatory%2C+Legal/12-MAR-08-Seroquel-trial-date-set/ArticleStandard/Article/detail/502953?ref=25 AstraZeneca alleges infringement of its patent against Teva and Sandoz. 2008-03-12T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/112008/502953null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Corporate+Strategy/12-MAR-08-f-star-Opens-Second-Cambridge-Research-S/ArticleStandard/Article/detail/502947?ref=25 The facility is to be located at the Babraham Research Campus. 2008-03-12T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/112008/502947null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Supply+Chain%2C+Technology/11-MAR-08-AZ-announces-CDM-agreement-with-Cognizan/ArticleStandard/Article/detail/501875?ref=25 The contract is for a period of five years with anticipated revenues of approximately $95 million. 2008-03-11T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/112008/501875null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Supply+Chain%2C+Technology/11-MAR-08-Cobra-enters-SARS-development-agreement/ArticleStandard/Article/detail/501877?ref=25 The company has not disclosed the name of its partner in the agreement. 2008-03-11T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/112008/501877null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Regulatory%2C+Legal/11-MAR-08-New-gout-treatment-receives-CHMP-positiv/ArticleStandard/Article/detail/501876?ref=25 Ipsen's Adenuric (febuxostat) 80mg and 120mg tablets received the opinion for the treatment of chronic hyperuricaemia in gout and has been recommended for marketing authorisation. 2008-03-11T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/112008/501876null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+R%26D/11-MAR-08-Evotec-and-InterMune-sign-second-discove/ArticleStandard/Article/detail/501878?ref=25 Under the second contract, Evotec will support InterMune's research efforts using their medicinal chemistry know-how. 2008-03-11T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/112008/501878null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Finance%2C+M%26A/11-MAR-08-PanGenetics-raises-E23-million-in-Series/ArticleStandard/Article/detail/501879?ref=25 The round was led by Edmond de Rothschild Investment Partners (EdRIP). 2008-03-11T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/112008/501879null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Finance%2C+M%26A/10-MAR-08-Azopharma-acquires-ADC/ArticleStandard/Article/detail/501880?ref=25 The newly-acquired company will operate under the name of ADMEquant Bioanalytical Services. 2008-03-10T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/112008/501880null HTML http://www.pharmexeceurope.com/europharmexec/News/07-Mar-08-Evergreening-allegations-cause-heartburn/ArticleStandard/Article/detail/501072?ref=25 NHS accuses Reckitt Benckiser of blocking generic 2008-03-07T05:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/102008/501072null HTML http://www.pharmexeceurope.com/europharmexec/News/3-March-08-DIA-set-for-India-expansion/ArticleStandard/Article/detail/499449?ref=25 Mumbai event signals the Drug Information Associations new three-year Indian initiative. 2008-03-03T05:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/102008/499449null HTML http://www.pharmexeceurope.com/europharmexec/News/29-Feb-08-UCB-reports-solid-revenue-for-2007/ArticleStandard/Article/detail/498969?ref=25 UCB announces its consolidated full year 2007 financial results. 2008-02-29T05:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/092008/498969null HTML http://www.pharmexeceurope.com/europharmexec/Articles%3A+Regulatory%2C+Legal/Excipients-Escape-Clampdown/ArticleStandard/Article/detail/498966?ref=25 Reflector welcomes an instance of common sense making a breakthrough in Brussels. 2008-02-29T05:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/092008/498966null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Finance%2C+M%26A/25-FEB-08-HemCon-to-acquire-Alltracel/ArticleStandard/Article/detail/494066?ref=25 The acquisition is being implemented by means of a Scheme of Arrangement under applicable Irish legislation. 2008-02-25T05:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/092008/494066null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+R%26D/25-FEB-08-Novartis-establishes-developing-world-va/ArticleStandard/Article/detail/494067?ref=25 The new centre will be located in Siena, close to the company's existing Vaccines and Diagnostics global research centre. 2008-02-25T05:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/092008/494067null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+R%26D/22-FEB-08-Astellas-wins-CHMP-nod-for-fungal-infect/ArticleStandard/Article/detail/493729?ref=25 CHMP decision a critical step towards European Commission approval for Mycamine 2008-02-22T05:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/082008/493729null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Regulatory%2C+Legal/22-FEB-08-AZ-to-appeal-Alabama-Medicaid-ruling/ArticleStandard/Article/detail/493976?ref=25 AstraZeneca intends to seek reconsideration or reversal of a verdict in the Montgomery County Circuit Court awarding $40 million in compensatory damages and $175 million in punitive damages for alleged false and misleading reporting of prices for drugs reimbursed by the Alabama State Medicaid Agency in the US. 2008-02-22T05:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/092008/493976null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Regulatory%2C+Legal/22-FEB-08-Bayer-sued-over-Kogenate/ArticleStandard/Article/detail/493618?ref=25 Novartis Vaccines and Diagnostics Inc and Novo Nordisc A/S allege infringement of a compound patent issued in 2006. 2008-02-22T05:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/082008/493618null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Corporate+Strategy/22-FEB-08-Almirall-appoints-UK-general-manager/ArticleStandard/Article/detail/493621?ref=25 Prior to his nomination, Carlos Gallardo worked at Almirall headquarters. 2008-02-22T05:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/082008/493621null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Finance%2C+M%26A/22-FEB-08-Affimed-raises-extra-E5-million-adds-3-t/ArticleStandard/Article/detail/493614?ref=25 The money raised will be used to fund Affimed's proprietary therapeutic antibody programmes. 2008-02-22T05:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/082008/493614null HTML http://www.pharmexeceurope.com/europharmexec/News/19-FEB-08-Merck-KGaAs-sales-up-operating-profits-d/ArticleStandard/Article/detail/492459?ref=25 Merck KGaA (Germany) has reported that its fourth-quarter 2007 net income soared but its operating profit fell 20.6%. 2008-02-19T05:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/082008/492459null HTML http://www.pharmexeceurope.com/europharmexec/News/19-Feb-08-MHRA-re-issues-Yellow-Card-to-pharmacist/ArticleStandard/Article/detail/492466?ref=25 MHRA is launching a six-week campaign to re-educate the public about the Yellow Card Scheme. 2008-02-19T05:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/082008/492466null HTML http://www.pharmexeceurope.com/europharmexec/Articles%3A+Sales+%26+Marketing/How-to-Read-Your-Prospect-Like-a-Book/ArticleStandard/Article/detail/492282?ref=25 Listening with your eyes: the importance of body language in the sales process. 2008-02-18T05:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/082008/492282null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Finance%2C+M%26A/14-FEB-08-AZ-forms-GI-company/ArticleStandard/Article/detail/491799?ref=25 AstraZeneca and Nomura Phase4 Ventures have signed a deal to form Albireo, a company focused on developing new treatments for gastrointestinal (GI) disorders. 2008-02-14T05:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/072008/491799null HTML http://www.pharmexeceurope.com/europharmexec/Brussels+Report/Animal-Traps/ArticleStandard/Article/detail/491819?ref=25 How will the long-threatened revision of the EU's twenty-year old legislation on animal testing affect the industry? 2008-02-14T05:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/072008/491819null HTML http://www.pharmexeceurope.com/europharmexec/Healthcare-Education-Services-extends-oncology-cou/ArticleStandard/Article/detail/491582?ref=25 Healthcare Education Services has announced details of two additional oncology specific courses to add to its comprehensive range of medical education for the pharmaceutical industry. 2008-02-13T05:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/072008/491582null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Finance%2C+M%26A/4-FEB-08-Galapagos-acheives-milestone/ArticleStandard/Article/detail/489130?ref=25 The milestone concerns the company's RA allliance with Janssen. 2008-02-04T05:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/062008/489130null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Finance%2C+M%26A/4-FEB-08-Circassia-raises-GBP-11-million/ArticleStandard/Article/detail/489132?ref=25 The UK company raised the funds through an oversubscribed second round funding. 2008-02-04T05:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/062008/489132null HTML http://www.pharmexeceurope.com/europharmexec/Recruitment%3A+Finance%2C+M%26A/4-FEB-08-New-CFO-new-HQ-for-Synosia/ArticleStandard/Article/detail/489131?ref=25 Phillipe Lutz will be based in Basel, Switzerland. 2008-02-04T05:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/062008/489131null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+R%26D/4-FEB-08-Direvo-MedImmune-collaborate-on-CNS/ArticleStandard/Article/detail/489099?ref=25 The companies have signed a research and license agreement to develop a therapeutic protease. 2008-02-04T05:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/062008/489099null HTML http://www.pharmexeceurope.com/europharmexec/Upcoming-events/ArticleStandard/Article/detail/500381?ref=25 Upcoming events: February 2008 2008-02-01T05:00:00Z http://www.pharmexeceurope.com/europharmexec/dat